Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Take part in our new study looking at flu vaccines

The Oxford Vaccine Group, part of the University of Oxford, would like to invite you and your child to take part in a study to investigate the immune response to a flu vaccine.

We are looking to enroll healthy Caucasian children aged 13 to 24 months, these children would receive two doses of a flu vaccine and three blood tests. Healthy Caucasian adults aged 18 to 65 years are also able to participate, they would receive one dose of a flu vaccine and four blood tests. We would use local anaesthetic cream on the skin to reduce any discomfort from the blood sampling.

You would have 24 hour telephone access to a paediatrician, should you have any concerns following vaccination. Taking part in this study is voluntary.

If you would like to any further information please visit:

Our website

You can also contact us by telephone on 01865 857420 or you can e-mail us at info@ovg.ox.ac.uk.

 

Similar stories

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.

Oral paratyphoid vaccine to begin human trials

The University of Oxford in collaboration with the University of Maryland School of Medicine (UMSoM) has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford.

Oxford scientist named Australian of the Year in the UK

The Oxford Vaccine Group’s Lead Statistician, Professor Merryn Voysey, received the prestigious Australian of the Year in the UK award at a gala dinner recently.

Angelman syndrome: first patient to receive potential therapy in Oxford

Things that seemed impossible, only a few years ago, are happening today. The first patient in Europe and one of the first in the world was injected with a potential treatment, GTX-102, in a phase I/II clinical trial in Oxford.

New model for infant leukaemia announced

The breakthrough could lead to development of new treatments for infant Acute Lymphoblastic Leukaemia.

Why it's so hard to treat pain in infants

For decades physicians believed that premature babies didn’t experience pain. Here’s what doctors know now – and the innovative solutions being embraced by today's caregivers.